tiprankstipranks
Trending News
More News >
CARsgen Therapeutics Holdings Ltd. (HK:2171)
:2171

CARsgen Therapeutics Holdings Ltd. (2171) Stock Statistics & Valuation Metrics

Compare
2 Followers

Total Valuation

CARsgen Therapeutics Holdings Ltd. has a market cap or net worth of HK$8.79B. The enterprise value is HK$6.25B.
Market CapHK$8.79B
Enterprise ValueHK$6.25B

Share Statistics

CARsgen Therapeutics Holdings Ltd. has 578,130,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding578,130,500
Owned by Insiders
Owned by Institutions

Financial Efficiency

CARsgen Therapeutics Holdings Ltd.’s return on equity (ROE) is -0.12 and return on invested capital (ROIC) is -20.83%.
Return on Equity (ROE)-0.12
Return on Assets (ROA)-0.07
Return on Invested Capital (ROIC)-20.83%
Return on Capital Employed (ROCE)-0.21
Revenue Per Employee263.25K
Profits Per Employee-205.01K
Employee Count465
Asset Turnover0.09
Inventory Turnover10.26

Valuation Ratios

The current PE Ratio of CARsgen Therapeutics Holdings Ltd. is ―. CARsgen Therapeutics Holdings Ltd.’s PEG ratio is 0.88.
PE Ratio
PS Ratio60.15
PB Ratio9.44
Price to Fair Value9.44
Price to FCF0.00
Price to Operating Cash Flow-30.36
PEG Ratio0.88

Income Statement

In the last 12 months, CARsgen Therapeutics Holdings Ltd. had revenue of 122.41M and earned -95.33M in profits. Earnings per share was -0.17.
Revenue122.41M
Gross Profit49.15M
Operating Income-229.15M
Pretax Income-100.24M
Net Income-95.33M
EBITDA-200.42M
Earnings Per Share (EPS)-0.17

Cash Flow

In the last 12 months, operating cash flow was -253.97M and capital expenditures 45.29M, giving a free cash flow of -208.68M billion.
Operating Cash Flow-253.97M
Free Cash Flow-208.68M
Free Cash Flow per Share-0.36

Dividends & Yields

CARsgen Therapeutics Holdings Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.60
52-Week Price Change14.46%
50-Day Moving Average15.03
200-Day Moving Average18.51
Relative Strength Index (RSI)51.57
Average Volume (3m)1.98M

Important Dates

CARsgen Therapeutics Holdings Ltd. upcoming earnings date is Aug 25, 2026, TBA (Confirmed).
Last Earnings DateMar 6, 2026
Next Earnings DateAug 25, 2026
Ex-Dividend Date

Financial Position

CARsgen Therapeutics Holdings Ltd. as a current ratio of 5.73, with Debt / Equity ratio of 7.85%
Current Ratio5.73
Quick Ratio5.70
Debt to Market Cap<0.01
Net Debt to EBITDA5.30
Interest Coverage Ratio-34.11

Taxes

In the past 12 months, CARsgen Therapeutics Holdings Ltd. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

CARsgen Therapeutics Holdings Ltd. EV to EBITDA ratio is -31.44, with an EV/FCF ratio of 0.00.
EV to Sales51.47
EV to EBITDA-31.44
EV to Free Cash Flow0.00
EV to Operating Cash Flow-27.30

Balance Sheet

CARsgen Therapeutics Holdings Ltd. has HK$1.12B in cash and marketable securities with HK$61.20M in debt, giving a net cash position of HK$1.06B billion.
Cash & Marketable SecuritiesHK$1.12B
Total DebtHK$61.20M
Net CashHK$1.06B
Net Cash Per ShareHK$1.84
Tangible Book Value Per ShareHK$1.41

Margins

Gross margin is 54.23%, with operating margin of -187.20%, and net profit margin of -77.88%.
Gross Margin54.23%
Operating Margin-187.20%
Pretax Margin-81.89%
Net Profit Margin-77.88%
EBITDA Margin-163.73%
EBIT Margin-187.20%

Analyst Forecast

The average price target for CARsgen Therapeutics Holdings Ltd. is HK$29.08, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$29.08
Price Target Upside95.30% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast1219.19%
EPS Growth Forecast25.15%

Scores

Smart Score5
AI Score